Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
26,205 people get JNJ articles and Market Currents by email alert.
Get email alerts on JNJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Johnson & Johnson's CEO Hosts Annual Meeting of Shareholders (Transcript)Thu, Apr 26, 2012 • 1 Comment
-
Johnson & Johnson Services, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Johnson & Johnson Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Johnson & Johnson Q4 2009 Earnings Call TranscriptTue, Jan 26, 2010
-
Johnson & Johnson Q3 2009 Earnings Call TranscriptTue, Oct 13, 2009
-
Johnson & Johnson Q2 2009 Earnings Call TranscriptTue, Jul 14, 2009
-
Johnson & Johnson F1Q09 (Qtr End 03/29/09) Earnings Call TranscriptTue, Apr 14, 2009 • 1 Comment
-
Johnson & Johnson Q4 2008 Earnings Call TranscriptTue, Jan 20, 2009
-
at CNBC.com (Fri, 1:43PM)
-
at CNBC.com (Fri, 11:27AM)
-
at MarketWatch.com (Fri, 7:00AM)
-
at CNBC.com (Tue, 4:06PM)
-
at MarketWatch.com (Tue, 8:46AM)
-
at MarketWatch.com (May 12, 2013)
-
at MarketWatch.com (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
JNJ vs. ETF Alternatives
Company Description
General
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 3, 5:08 PM Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment. 1 Comment [Healthcare, M&A]
- Thursday, January 3, 11:43 AM Maybe less entertaining than Byron Wien, but almost surely more actionable is this list of predictions for 2013 from Ploutos. Among the ideas is outperformance by DELL and HPQ thanks to activist investors taking major stakes. A big purchase by Berkshire Hathaway (BRK.B) is being talked about, and Ploutos guesses it will be Cummins (CMI). Will JNJ give up its AAA rating to lever up and return cash to shareholders? 5 Comments [Quick Ideas]
- Wednesday, January 2, 12:23 PM Johnson & Johnson (JNJ) declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.46%. For shareholders of record Feb. 26. Payable Mar. 12. Ex-div date Feb. 22. (PR) Comment! [Dividends]
- Monday, December 31, 2012, 9:41 AM The FDA OKs J&J's (JNJ -0.2%) Sirturo drug for treating tuberculosis in patients who don't respond to other medicines. Sirturo is the first drug in four decades to fight TB using a new mechanism - the treatment blocks an enzyme that's vital for the survival of TB bacteria. The FDA authorization comes after only Phase II of trials - J&J is due to start Phase III in Q1 2013 - and despite more patients dying than with other drugs. Comment! [Healthcare]
- Wednesday, December 19, 2012, 8:03 PM Shares of Vivus (VVUS) are active in the post session on speculation that Johnson & Johnson (JNJ) and AstraZeneca (AZN) are considering a takeover of the drug developer due to the company's obesity drug Qsymia. Pfizer (PFE) may also take an interest should VVUS come under takeover attack, because obestity drugs are a hot item at present - with over 78M obese adults in the U.S. alone. Deal-watchers are skeptical however, noting that any deal with a chance of success would need to be in the $30-plus per share range. VVUS +1.3% AH. 1 Comment [Healthcare, M&A, On the Move]
- Wednesday, December 19, 2012, 7:25 PM The FDA says that the blood thinner Pradaxa is not safe for use on patients with mechanical heart valves. A clinical trial in Europe was recently stopped because users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin. There was also more bleeding after valve surgery in Pradaxa users than in warfarin users. Pradaxa's competitors include: Eliquis, from Bristol-Myers Squibb (BMY) and Pfizer (PFE), Xarelto from Johnson & Johnson (JNJ) and Coumadin, an older drug that's also from BMY. 4 Comments [Healthcare]
- Tuesday, December 18, 2012, 6:15 PM The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ. 14 Comments [Quick Ideas]
- Saturday, December 15, 2012, 10:30 AM After a stretch in which it alienated the infinitely patient Warren Buffett, Johnson & Johnson (JNJ) may be poised for strong performance, writes Andrew Bary. While the Oracle was selling, the Street was starting to warm up to the company. Revenue growth is improving, and the dividend - the stock yields 3.45% - should continue to grow at 8% annually for years. Underweight institutional investors might soon find themselves needing to buy. 5 Comments [Healthcare, Quick Ideas]
- Monday, December 10, 2012, 2:30 PM Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a broader indication for Zytiga. The drug, in combination with prednisone, may now be used earlier in the treatment continuum, before the use of chemotherapy. Zytiga also received a positive opinion for an expanded indication from the EMA and is under review by other health authorities worldwide. 1 Comment [Healthcare, Global & FX]
- Sunday, December 9, 2012, 3:42 AM Pharmacyclics's (PCYC) and J&J's (JNJ) ibrutinib for chronic lymphocytic leukemia slowed the progression of the blood cancer when used alone and with Roche's Rituxan in early to mid-stage trials. On its own, ibrutinib stopped the disease worsening for 26 months in 96% of untreated patients and in 75% of those that had relapsed or were at risk of doing so. (PR) Comment! [Healthcare]
- Sunday, December 9, 2012, 3:28 AM Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR) 5 Comments [Healthcare, Top Stories]
- Tuesday, December 4, 2012, 11:42 AM Many U.S. firms are cash rich abroad but cash poor at home, and the SEC worries they aren’t presenting investors with an honest appraisal of their liquidity. “That doesn’t mean they could suddenly run out of money to pay their bills," WSJ's Kate Linebaugh writes. "But it does mean there could be unseen limits on their ability to pay dividends and buy back shares." 36 Comments [U.S. Economy, Global & FX]
- Tuesday, December 4, 2012, 9:54 AM An Australian judge has approved a settlement between J&J (JNJ) and patients who received dodgy knee implants, clearing the way for the company to pay compensation of at least A$30,000 ($31,000) per case. J&J recalled the implant in 2009 following reports of defects. Over 5,070 implants were used in Australia, while the number of inquiries about the proposed deal is over 430. Comment! [Healthcare]
- Tuesday, December 4, 2012, 8:13 AM An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court. 9 Comments
- Friday, November 30, 2012, 9:17 AM Johnson & Johnson (JNJ) CEO Alex Gorsky is elected Chairman of the Board. Current chairman Bill Weldon will step down on Dec. 28. Weldon was also CEO before being replaced by Gorsky earlier this year. (PR) Comment! [Healthcare, Breaking News]
- Thursday, November 29, 2012, 9:38 AM J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and other poor countries, allowing generic pharmaceutical companies to manufacture cheap versions of the drug as long as the quality remains high. However, J&J won't share its IP in the new Medicines Patent Pool, saying it wants "to reserve the right to reinforce patents." Comment! [Healthcare]
-
- View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Stock Model (TSM) Momentum 3/6/2013 (Wednesday): (1-2-3) <$JNJ $KSU $SU> Johnson & Johnson ($JNJ) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 0 replies
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 2/21/2013 (Thursday): (1-2-3) Johnson & Johnson ($JNJ) Perrigo ($PRGO) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
Dividend Sheet
$JNJ $MHFI $MUSA and $DK are the only stocks going ex-dividend tomorrow - http://stks.co/iMRK - View all 0 replies
-
Vash Patel
Ever really thought about whether dividend stocks outperform the market or not? http://bit.ly/12ChyAC $SPY $WMT $MCD $XOM $MMM $KO $PEP $JNJ - View all 0 replies
-
Dividend Sheet
$VVC $NWN and $DBD are the best yielding Dividend Kings - http://stks.co/p2WV - I like $KO $PG and $JNJ - View all 0 replies
-
Jim Van Meerten
$JNJ - 96% Barchart technical buys signals - 12 new highs and up 4.19% in the last month - Relative Strength Index 71.38% - View all 0 replies
-
Dividend Sheet
$BX $GSK and $TOT are the best yielding and most bought dividend stocks from investment gurus + http://stks.co/bKV1 + I like $INTC and $JNJ - View all 1 replies
-
-
O. Young Kwon
TANER Stock Model [TSM] Momentum 2/11/2013 (Monday): (1-2-3) <$JNJ $CME $EDU)> Johnson & Johnson ($JNJ) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
LATEST REPLIES
-
- View all 2 replies
-
O. Young Kwon: 2 = 2-month term. Momentum can help you (a) to manage your portfolios piecemeal, not on-off fashion,<c>
-
O. Young Kwon: and (b) to decide what securities (ETFs and Stocks) to buy, sell, or hold. yk
-
- View all 2 replies
-
O. Young Kwon: 1 = 1-m term. T (Topping): Leading Leaders (LDLD). A (Advancing): Lagging Leaders (LGLD), <c>
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/3/2012, Tuesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
neobliviscar
WHat are some other good shorts? Hate to do JNJ since it has been a div darling, but it is a bit out of whack price wise. Others? - View all 2 replies
-
-
-
- View all 3 replies
-
-
neobliviscar: *sigh*. Giving back 1/2 of what I made on the oversell. Bipolar market.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (619/2012, Tuesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
Alan Brochstein
$JNJ move last week was one of the largest historically, especially outside of an earnings report. - View all 4 replies
-
madpup: If Obama Care goes down, drug stocks may go down also, these companies sold out on the U.S., so as to make an inside deal for themselves. -
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (618/2012, Monday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: 1 = 1-m term. T (Topping): Leading Leaders (LDLD). A (Advancing): Lagging Leaders (LGLD), <c>
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (615/2012, Friday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (614/2012, Thursday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 1 replies
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (613/2012, Wednesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (612/2012, Tuesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (611/2012, Monday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.